PeuskensJ. Risperidone in the treatment of patients with chronic schizophrenia: A multi-national, multicentre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. Br J Psychiatry1995;166: 712–26.
2.
SchillevoortIde BoerAHeringsRMRoosRAJansenPALeufkensHG. Antipsychotic-induced extrapyramidal syndromes. Risperidone compared with low- and high-potency conventional antipsychotic drugs. Eur J Clin Pharmacol2001;57: 327–31.
3.
SloneDShapiroSMiettinenOSFinkleWDStolleyPD. Drug evaluation after marketing. Ann Intern Med1979;90: 257–61.
4.
CaligiuriMPLohrJB. Instrumental motor predictors of neuroleptic-induced parkinsonism in newly medicated schizophrenia patients. J Neuropsychiatry Clin Neurosci1997;9: 562–7.
5.
MillerCHHummerMOberbauerHKurzthalerIDeColCFleischhackerWW. Risk factors for the development of neuroleptic induced akathisia. Eur Neuropsychopharmacol1997;7: 51–5.
6.
NybergSFardeL. Non-equipotent doses partly explain differences among antipsychotics — Implications of PET studies. Psychopharmacology (Berl)2000;148: 22–3.
7.
MarderSR. Risperidone: Clinical development: North American results. Clin Neuropharmacol1992;15(suppl 1pt A):92a–3a.
8.
ChouinardGJonesBRemingtonGBloomDAddingtonDMacEwanGWA Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol1993;13: 25–40.
9.
CsernanskyJGMahmoudRBrennerR. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med2002;346: 16–22.
10.
FleischhackerWWMeiseUGuntherVKurzM. Compliance with antipsychotic drug treatment: Influence of side effects. Acta Psychiatr Scand Suppl1994;382: 11–5.
11.
HummerMFleischhackerWW. Compliance and outcome in patients treated with antipsychotics — The impact of extrapyramidal syndromes. CNS Drugs1996;5(S1):13–20.
12.
GeddesJ. Prevention of relapse in schizophrenia. N Engl J Med2002;346: 56–8.
